Interview with Dejan Jovanovic, General manager, Astellas Russia
When our team interviewed Amit Makwana at Astellas’ European Headquarters in the UK, he noted that the Russian affiliate is experiencing a huge growth rate that is very difficult for…
Address: 109147, Moscow,Russia
Tel: +7 (495) 737 0755
Web: http://www.astellas.com/worldwide.html
Pharma (the Netherlands), its Representative office was opened in Moscow in 1994. Yamanouchi Company was found on the basis of Brocades Company. In 2005 a new multinational company Astellas was found as a result of two Japanese companies’ merger – Fujisawa and Yamanouchi. Main Astellas goal is to improve people’s lives and give them hope for the future with innovative pharmaceutical products and also become a Global Category Leader in chosen therapy areas.
Astellas is among top 20 companies of the world successfully managing its business in different countries such as Japan, North America (the USA and Canada), Europe and Asia. Headcount of Astellas worldwide is more than 17 thousand people.
Russian affiliate is related to European branch – Astellas Pharma Europe. Astellas Russia is responsible for business in Russia, the Ukraine, Belarus, Kazakhstan, Azerbaijan, Armenia, Moldova, Georgia, Kirgizia, Turkmenistan, Tajikistan, Uzbekistan and Mongolia.
Astellas has 4 global corporate principals which are called STAR: Success driven, Team oriented, Adoptable and Respectful.
Russian affiliate headcount is continuingly growing. They are young and vigorous professionals who can achieve their ambitious goals. Astellas aim is to become an Employer of Choice. That is why it is trying to improve HR policy, social package and team spirit.
Infectives, Transplantation, Oncology, Pail Management and others. Astellas brand products are: Omnic, Prograf, Flemoxin Solutab, Wilprafen Solutab, Unidox Solutab, Pimafucin, Zineryt, DeNol, Phosphalugel and others.
When our team interviewed Amit Makwana at Astellas’ European Headquarters in the UK, he noted that the Russian affiliate is experiencing a huge growth rate that is very difficult for…
Although Russian authorities received heavy criticism for approving the Sputnik V vaccine prior to the completion of Phase III clinical trials, the jab is increasingly being seen as a viable…
Russia has announced that a domestically developed COVID-19 vaccine has been approved by its health authorities, the first such approval globally. However, with large-scale Phase III trials having not yet…
Below is a selection of top stories in Russian pharma from recent months, ranging from proposed changes in legislation, labelling system updates, priorities set forth by the country’s manufacturing association…
Russia is facing a drug shortage crisis which is having a particular impact on patients with life-threatening conditions. A combination of geopolitical and bureaucratic issues are restricting the flow of…
In the latest twist in the ongoing story of Russian interference in the US presidential elections of 2016, it has emerged that Russian internet trolls and automated bots spread misinformation…
In the United States, Johnson & Johnson has an image of being very close to people. Americans grow up with this company — from baby shampoo, to Tylenol when they…
You took over this organization just three months ago, having previously headed businesses in industries as diverse as retail, food, and automobiles. What drew you to Alliance Healthcare Russia? Do…
The ARPM was founded in 2002, and you were its director from 2002-2004, before leaving for a post at the Roszdravnadzor. You’ve since rejoined as director since 2007. The organization…
When Focus Reports prepared a report on the French pharmaceutical industry in 2009/10, we found that the head of the main multinational pharmaceutical association had taken a career path quite…
The U.S. and Russia have a long history of trade, and you have personally been with the American Chamber of Commerce in Russia since 2001. Can you give a brief…
The primary objectives of this association are to promote Russia as a clinical trial destination, optimize the regulatory and legislative environment, and promote the interests of ACTO members. Can you…
You have said that AstraZeneca intends to be “in Russia for Russia” and the company has recently announced a large-scale investment in this country, financing a $150Mn domestic facility in…
See our Cookie Privacy Policy Here